Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) closed at $2.69 up 30.58% from its previous closing price of $2.06. In other words, the price has increased by $30.58 from its previous closing price. On the day, 4.99 million shares were traded. MRVI stock price reached its highest trading level at $2.7 during the session, while it also had its lowest trading level at $2.3.
Ratios:
For a deeper understanding of Maravai LifeSciences Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.49 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 1.40 whereas as Long-Term Debt/Eq ratio is at 1.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on February 26, 2025, Downgraded its rating to Neutral and sets its target price to $3 from $9 previously.
Goldman Downgraded its Neutral to Sell on December 05, 2024, while the target price for the stock was maintained at $4.25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 31 ’25 when ORESHACK KURT sold 25,000 shares for $5.03 per share. The transaction valued at 125,750 led to the insider holds 167,618 shares of the business.
ORESHACK KURT bought 25,000 shares of MRVI for $125,750 on Jan 31 ’25. On Nov 12 ’24, another insider, DeFord John A, who serves as the Director of the company, bought 17,500 shares for $5.75 each. As a result, the insider paid 100,625 and bolstered with 70,046 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRVI now has a Market Capitalization of 984663808 and an Enterprise Value of 622183424. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.17 while its Price-to-Book (P/B) ratio in mrq is 1.46. Its current Enterprise Value per Revenue stands at 2.573 whereas that against EBITDA is -15.599.
Stock Price History:
The Beta on a monthly basis for MRVI is 0.29, which has changed by -0.6727494 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, MRVI has reached a high of $9.95, while it has fallen to a 52-week low of $1.66. The 50-Day Moving Average of the stock is 12.68%, while the 200-Day Moving Average is calculated to be -25.90%.
Shares Statistics:
For the past three months, MRVI has traded an average of 1.81M shares per day and 2044380 over the past ten days. A total of 144.62M shares are outstanding, with a floating share count of 103.48M. Insiders hold about 28.13% of the company’s shares, while institutions hold 76.21% stake in the company. Shares short for MRVI as of 1752537600 were 14380643 with a Short Ratio of 7.37, compared to 1749772800 on 13048449. Therefore, it implies a Short% of Shares Outstanding of 14380643 and a Short% of Float of 11.88.
Earnings Estimates
The stock of Maravai LifeSciences Holdings Inc (MRVI) is currently in the spotlight, with 11.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.03 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.23 and -$0.38 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.21, with 12.0 analysts recommending between -$0.07 and -$0.47.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $48.89M this quarter.It ranges from a high estimate of $53.9M to a low estimate of $45.45M. As of the current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $65.2MFor the next quarter, 12 analysts are estimating revenue of $49.04M. There is a high estimate of $55.8M for the next quarter, whereas the lowest estimate is $44.02M.
A total of 13 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $203.5M, while the lowest revenue estimate was $185.4M, resulting in an average revenue estimate of $192.47M. In the same quarter a year ago, actual revenue was $259.19MBased on 12 analysts’ estimates, the company’s revenue will be $207.38M in the next fiscal year. The high estimate is $230.4M and the low estimate is $192M.
